MetaCap

Biofrontera (BFRI) vs CalciMedica (CALC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Biofrontera (BFRI) has outperformed CalciMedica (CALC) over the past year, losing 28.4% versus a loss of 92.3%. Biofrontera is the larger company by market cap ($9.5 million vs $8.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BFRI-28.38%CALC-92.34%
+128%+12%-104%
Nov 21, 20251 yearNov 20, 2026
BFRI-93.98%CALC-94.99%
+43%-30%-102%
Jun 12, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BFRI versus CALC key metrics
MetricBFRICALC
Share price$0.53$1.26
Market cap$9.51M$8.69M
1-day change-7.02%+7.69%
YTD return-7.02%-96.18%
1-year return-28.38%-92.34%
5-year return-99.66%—
Forward P/E1.32—
EPS (TTM)$-0.26$-4.41
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$41.70M—
Revenue growth (YoY)+11.75%—
Net income (latest FY)$-10.54M$-29.56M
Operating margin-27.21%—
Net margin-25.26%—
52-week high$1.66$36.00
52-week low$0.53$1.00
Distance from 52-week high-68.07%-96.50%
Analyst consensusnonenone
Avg. price target upside+1032.08%+3868.25%
Average volume429.04K80.15K
Shares outstanding17.95M6.90M
Employees8415
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BFRI has outperformed CALC by 64.0 percentage points over the past year.

About Biofrontera

BFRI stock →

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions.

Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees

About CalciMedica

CALC stock →

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

BFRI vs CALC FAQ

Which is bigger, Biofrontera or CalciMedica?

Biofrontera (BFRI) is larger, with a market capitalization of $9.51M compared with $8.69M for CalciMedica (CALC).

Which stock has performed better over the past year, BFRI or CALC?

BFRI returned -28.38% over the past 12 months, compared with -92.34% for CALC (price return, excluding dividends). Past performance does not predict future results.

Are Biofrontera and CalciMedica in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons